GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Additional Paid-In Capital

Microba Life Sciences (ASX:MAP) Additional Paid-In Capital : A$0.00 Mil(As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Additional Paid-In Capital?



Microba Life Sciences Additional Paid-In Capital Historical Data

The historical data trend for Microba Life Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Additional Paid-In Capital Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23
Additional Paid-In Capital
- -

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital - - - - -

Microba Life Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Microba Life Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Microba Life Sciences (ASX:MAP) Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines